Loading
Valrubicin (Valstar) is a chemotherapy washed into the bladder for carcinoma in situ that has not responded to BCG, in patients who cannot yet have their bladder removed.
Valrubicin was approved in September 1998 for intravesical therapy of BCG-refractory carcinoma in situ of the urinary bladder in patients for whom immediate cystectomy would carry unacceptable morbidity or mortality. In the pivotal experience, 230 patients received the drug and about one in five with refractory CIS had a complete response, mostly not durable, so it is a bridge rather than a cure; the label stresses that delaying cystectomy risks progression. Newer options for BCG-unresponsive disease (pembrolizumab, nadofaragene firadenovec, nogapendekin alfa inbakicept, TAR-200) have reduced its use. Irritative bladder symptoms and red-tinged urine are expected.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
Semi-synthetic anthracycline analogue of doxorubicin instilled into the bladder; inhibits nucleoside incorporation into nucleic acids and topoisomerase II, arresting cells in G2.
1.Valrubicin slips into a pocket on its target.
Background: ADC sequencing, Antigen escape (antigen loss, lineage switch), BCG-unresponsive, Castration-resistant prostate cancer (CRPC), Circulating tumour DNA (ctDNA). Also on OnCo: Resistance: how tumours escape each drug class · Lines of therapy.
| Region | Year | Indication |
|---|---|---|
| US | 1998 | Intravesical therapy of BCG-refractory carcinoma in situ of the bladder when immediate cystectomy is not acceptable |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Valrubicin" OR ABSTRACT:"Valrubicin" OR TITLE:"Valstar" OR ABSTRACT:"Valstar") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Valrubicin, not a curated reading list.
Shares Nadofaragene firadenovec, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
Shares Nadofaragene firadenovec, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
Shares Nadofaragene firadenovec, Nogapendekin alfa inbakicept, Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
Shares Nogapendekin alfa inbakicept, Bladder & urothelial cancer.
Shares Nogapendekin alfa inbakicept, Bladder & urothelial cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.
Shares Intravesical therapy (BCG, chemotherapy, devices, gene and viral therapy), Bladder & urothelial cancer.